At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Suvorexant and Trauma Related Insomnia
In Brief
A Phase 4 clinical trial evaluating suvorexant and placebo for Insomnia and Posttraumatic Stress Disorder. Completed, enrolled 41 participants across 1 site.
Detailed Summary
Problems sleeping are common after exposure to highly threatening experiences and can occur with and without a diagnosis of posttraumatic stress disorder (PTSD). Established treatments for PTSD are limited for addressing insomnia and many insomnia treatments appear to be limited in the context of PTSD. Suvorexant is FDA approved for insomnia and among approved drugs has a unique mechanism of action that may be well suited for targetting arousal at night dysregulated by trauma. The investigators will evaluate the efficacy of suvorexant for insomnia that developed in relation to trauma exposure, utilizing a placebo control, and polysomnography to identify biomarkers of response, in a six week trial.
Study Details
Timeline
Interventions
First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
Pill with inactive ingredients